SCHEMBL6076970

SCHEMBL6076970

COC(=O)C(O)=CC(=O)N(Cc1ccc(F)cc1)OCC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 1/20 0.38
KDM1A O60341 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KCNQ4 P56696 3/20 0.36
KCNQ5 Q9NR82 3/20 0.36
CA12 O43570 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
CA1 P00915 1/20 0.35
RIPK1 Q13546 2/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
CTNNB1 P35222 1/20 0.33
TCF7L2 Q9NQB0 1/20 0.33
CA7 P43166 1/20 0.32
CA14 Q9ULX7 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076961 1.00 NR1D1 (0.38) NR1D1KDM1AHDAC8HDAC6KCNQ4
SCHEMBL6872054 0.90 NR1D1 (0.39) NR1D1KDM1AHDAC8HDAC6KCNQ4
SCHEMBL6872051 0.90 NR1D1 (0.39) NR1D1KDM1AHDAC8HDAC6KCNQ4
SCHEMBL6077534 0.84 ALDH1A1 (0.38) CA12CA2CA9CA1RIPK1
SCHEMBL6076879 0.83 CA12 (0.40) CA12CA2CA9CA1RIPK1
SCHEMBL6076881 0.83 CA12 (0.40) CA12CA2CA9CA1RIPK1
SCHEMBL6077249 0.81 CA12 (0.42) CA12CA2CA9CA1RIPK1
SCHEMBL6077241 0.81 CA12 (0.42) CA12CA2CA9CA1RIPK1
SCHEMBL6076427 0.80 CA12 (0.38) CA12CA2CA9CA1CA7
SCHEMBL6076423 0.80 CA12 (0.38) CA12CA2CA9CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF NR1D1 2254/4885KDM1A 228/4885HDAC8 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.